Opportunities and challenges of long term anti-estrogenic adjuvant therapy: treatment forever or intermittently?

References

• Miller KD, Siegel RL, Lin CC, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016;66:271–289.
   PubMed Web of Science ®Google Scholar
• Rosenberg PS, Barker KA, Anderson WF. Estrogen receptor status and the future burden of invasive and in situ breast cancers in the United States. J Natl Cancer Inst. 2015;107.
   Google Scholar
• Jensen EV, Jordan VC. The estrogen receptor: a model for molecular medicine. Clin Cancer Res. 2003;9:1980–1989.
   PubMed Web of Science ®Google Scholar
• Sledge GW, Mamounas EP, Hortobagyi GN, et al. Past, present, and future challenges in breast cancer treatment. J Clin Oncol. 2014;32:1979–1986.
   PubMed Web of Science ®Google Scholar
• Jordan VC. Tamoxifen: a most unlikely pioneering medicine. Nat Rev Drug Discov. 2003;2:205–213.
   PubMed Web of Science ®Google Scholar
• Jordan VC. Tamoxifen as the first targeted long-term adjuvant therapy for breast cancer. Endocr Relat Cancer. 2014;21:R235–R246.
   PubMed Web of Science ®Google Scholar
• Hubay CA, Pearson OH, Marshall JS, et al. Adjuvant chemotherapy, antiestrogen therapy and immunotherapy for stage II breast cancer: 45-month follow-up of a prospective, randomized clinical trial. Cancer. 1980;46:2805–2808.
   PubMed Web of Science ®Google Scholar
• Ribeiro G, Palmer MK. Adjuvant tamoxifen for operable carcinoma of the breast: report of clinical trial by the Christie Hospital and Holt Radium Institute. Br Med J (Clin Res Ed). 1983;286:827–830.
   PubMed Web of Science ®Google Scholar
• Rose C, Thorpe SM, Andersen KW, et al. Beneficial effect of adjuvant tamoxifen therapy in primary breast cancer patients with high oestrogen receptor values. Lancet. 1985;1:16–19.
   PubMed Web of Science ®Google Scholar
• Ribeiro G, Swindell R. The Christie Hospital tamoxifen (Nolvadex) adjuvant trial for operable breast carcinoma–7-yr results. Eur J Cancer Clin Oncol. 1985;21:897–900.
   PubMedGoogle Scholar
• Cummings FJ, Gray R, Davis TE, et al. Adjuvant tamoxifen treatment of elderly women with stage II breast cancer. A double-blind comparison with placebo. Ann Intern Med. 1985;103:324–329.
   PubMed Web of Science ®Google Scholar
• Baum M, Brinkley DM, Dossett JA, et al. Controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer. Analysis at six years by nolvadex adjuvant trial organisation. Lancet. 1985;1:836–840.
   PubMed Web of Science ®Google Scholar
• Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC), Edinburgh. Adjuvant tamoxifen in the management of operable breast cancer: the Scottish Trial. Lancet. 1987;2:171–175.
   PubMed Web of Science ®Google Scholar
• Fisher B, Costantino J, Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med. 1989;320:479–484.
   PubMed Web of Science ®Google Scholar
• Jordan VC. Long-term adjuvant tamoxifen therapy for breast cancer. Breast Cancer Res Treat. 1990;15:125–136.
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. N Engl J Med. 1988;319:1681–1692.
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet. 1992;339:71–85.
   PubMedGoogle Scholar
• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998;351:1451–1467.
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687–1717.
   PubMed Web of Science ®Google Scholar
• Davies C, Godwin J, Gray R, et al. Early breast cancer trialists’ collaborative group (EBCTCG). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378:771–784.
   PubMed Web of Science ®Google Scholar
• Jordan VC. Biochemical pharmacology of antiestrogen action. Pharmacol Rev. 1984;36:245–276.
   PubMed Web of Science ®Google Scholar
• Sutherland RL, Green MD, Hall RE, et al. Tamoxifen induces accumulation of MCF 7 human mammary carcinoma cells in the G0/G1 phase of the cell cycle. Eur J Cancer Clin Oncol. 1983;19:615–621.
   PubMedGoogle Scholar
• Osborne CK, Boldt DH, Clark GM, et al. Effects of tamoxifen on human breast cancer cell cycle kinetics: accumulation of cells in early G1 phase. Cancer Res. 1983;43:3583–3585.
   PubMed Web of Science ®Google Scholar
• Schiavon G, Smith IE. Status of adjuvant endocrine therapy for breast cancer. Breast Cancer Res. 2014;16:206.
   PubMed Web of Science ®Google Scholar
• Blok EJ, Derks MG, van der Hoeven JJ, et al. Extended adjuvant endocrine therapy in hormone-receptor positive early breast cancer: current and future evidence. Cancer Treat Rev. 2015;41:271–276.
   PubMed Web of Science ®Google Scholar
• Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381:805–816.
   PubMed Web of Science ®Google Scholar
• Gray RG, Handley K, Marshall A, et al. aTTom (adjuvant Tamoxifen—to offer more?): randomized trial of 10 versus 5 years of adjuvant tamoxifen among 6,934 women with estrogen receptor-positive (ER+) or ER untested breast cancer—preliminary results. J Clin Oncol. 2008;26:513.
   Web of Science ®Google Scholar
• Goss PE, Ingle JN, Pritchard KI, et al. Extending aromatase-inhibitor adjuvant therapy to 10 years. N Engl J Med. 2016;375:209–219.
   PubMed Web of Science ®Google Scholar
• Colleoni M. OT2-02-01: the sole trial: international breast cancer study group (IBCSG 35–07) and breast international group (BIG 1–07) study of letrozole extension. Cancer Res. 2011;71.
   Web of Science ®Google Scholar
• Jordan VC, Curpan R, Maximov PY. Estrogen receptor mutations found in breast cancer metastases integrated with the molecular pharmacology of selective ER modulators. J Natl Cancer Inst. 2015;107:75.
   Google Scholar
• Segal CV, Dowsett M. Estrogen receptor mutations in breast cancer–new focus on an old target. Clin Cancer Res. 2014;20:1724–1726.
   PubMed Web of Science ®Google Scholar
• Jordan VC. The new biology of estrogen-induced apoptosis applied to treat and prevent breast cancer. Endocr Relat Cancer. 2015;22:1–31.
   PubMed Web of Science ®Google Scholar
• Jordan VC, Fan P, Abderrahman B, et al. Sex steroid induced apoptosis as a rational strategy to treat anti-hormone resistant breast and prostate cancer. Discov Med. 2016;21:321–337.
   Web of Science ®Google Scholar
• Pan HGR, Davies C, Peto R, et al. Long term recurrence risks afetr use of endocrine therapy for only 5 years. ASCO Annu Meet. 2016. Abstract 505. Available from: http://meetinglibrary.asco.org/content/166053-176
   Google Scholar
• Tormey DC, Jordan VC. Long-term tamoxifen adjuvant therapy in node-positive breast cancer: a metabolic and pilot clinical study. Breast Cancer Res Treat. 1984;4:297–302.
   PubMed Web of Science ®Google Scholar
• Tormey DC, Rasmussen P, Jordan VC. Long-term adjuvant tamoxifen study: clinical update. Breast Cancer Res Treat. 1987;9:157–158.
   PubMed Web of Science ®Google Scholar
• Langan-Fahey SM, Tormey DC, Jordan VC. Tamoxifen metabolites in patients on long-term adjuvant therapy for breast cancer. Eur J Cancer. 1990;26:883–888.
   PubMed Web of Science ®Google Scholar
• Jordan VC. Use of the DMBA-induced rat mammary carcinoma system for the evaluation of tamoxifen treatment as a potential adjuvant therapy. Endocr Rel Cancer. 1978;49–55.
   Google Scholar
• Jordan VC, Dix CJ, Allen KE. The effectiveness of long term tamoxifen treatment in a laboratory model for adjuvant hormone therapy of breast cancer. Adjuvant Therapy Cancer II. 1979;19–26.
   Google Scholar
• Jordan VC, Allen KE. Evaluation of the antitumour activity of the non-steroidal antioestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model. Eur J Cancer. 1980;16:239–251.
   PubMed Web of Science ®Google Scholar
• Jordan VC, Naylor KE, Dix CJ, et al. Anti-oestrogen action in experimental breast cancer. Recent Results Cancer Res. 1980;71:30–44.
   PubMedGoogle Scholar
• Jordan VC, Allen KE, Dix CJ. Pharmacology of tamoxifen in laboratory animals. Cancer Treat Rep. 1980;64:745–759.
   PubMedGoogle Scholar
• Jordan VC. Laboratory studies to develop general principles for the adjuvant treatment of breast cancer with antiestrogens: problems and potential for future clinical applications. Breast Cancer Res Treat. 1983;3(Suppl):S73–S86.
   PubMed Web of Science ®Google Scholar
• Gottardis MM, Jordan VC. Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model. Cancer Res. 1987;47:4020–4024.
   PubMed Web of Science ®Google Scholar
• Lippman ME, Bolan G. Oestrogen-responsive human breast cancer in long term tissue culture. Nature. 1975;256:592–593.
   PubMed Web of Science ®Google Scholar
• Gottardis MM, Robinson SP, Jordan VC. Estradiol-stimulated growth of MCF-7 tumors implanted in athymic mice: a model to study the tumoristatic action of tamoxifen. J Steroid Biochem. 1988;30:311–314.
   PubMedGoogle Scholar
• Jordan VC, Lababidi MK, Mirecki DM. Anti-oestrogenic and anti-tumour properties of prolonged tamoxifen therapy in C3H/OUJ mice. Eur J Cancer. 1990;26:718–721.
   PubMed Web of Science ®Google Scholar
• Jordan VC, Lababidi MK, Langan-Fahey S. Suppression of mouse mammary tumorigenesis by long-term tamoxifen therapy. J Natl Cancer Inst. 1991;83:1488–1491.
   PubMedGoogle Scholar
• Falkson HC, Gray R, Wolberg WH, et al. Adjuvant trial of 12 cycles of CMFPT followed by observation or continuous tamoxifen versus four cycles of CMFPT in postmenopausal women with breast cancer: an Eastern cooperative oncology group phase III study. J Clin Oncol. 1990;8:599–607.
   PubMed Web of Science ®Google Scholar
• Stewart HJ, Forrest AP, Everington D, et al. Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. The Scottish cancer trials breast group. Br J Cancer. 1996;74:297–299.
   PubMed Web of Science ®Google Scholar
• Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst. 1996;88:1529–1542.
   PubMed Web of Science ®Google Scholar
• Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003;349:1793–1802.
   PubMed Web of Science ®Google Scholar
• Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst. 2005;97:1262–1271.
   PubMed Web of Science ®Google Scholar
• Jordan VC, Fritz NF, Langan-Fahey S, et al. Alteration of endocrine parameters in premenopausal women with breast cancer during long-term adjuvant therapy with tamoxifen as the single agent. J Natl Cancer Inst. 1991;83:1488–1491.
   PubMedGoogle Scholar
• Bonadonna G, Brusamolino E, Valagussa P, et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med. 1976;294:405–410.
   PubMed Web of Science ®Google Scholar
• Azim HA Jr., de Azambuja E, Colozza M, et al. Long-term toxic effects of adjuvant chemotherapy in breast cancer. Ann Oncol. 2011;22:1939–1947.
   PubMed Web of Science ®Google Scholar
• Goldhirsch A, Gelber RD, Yothers G, et al. Adjuvant therapy for very young women with breast cancer: need for tailored treatments. J Natl Cancer Inst Monogr. 2001;30:44–51.
   PubMedGoogle Scholar
• Pagani O, Regan MM, Walley BA, et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med. 2014;371:107–118.
   PubMed Web of Science ®Google Scholar
• Francis PA, Regan MM, Fleming GF, et al. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med. 2015;372:436–446.
   PubMed Web of Science ®Google Scholar
• Colleoni M, Munzone E. Picking the optimal endocrine adjuvant treatment for pre-menopausal women. Breast. 2015;24(Suppl 2):S11–S14.
   PubMed Web of Science ®Google Scholar
• Burstein HJ, Lacchetti C, Anderson H, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American society of clinical oncology clinical practice guideline update on ovarian suppression. J Clin Oncol. 2016;34:1689–1701.
   PubMed Web of Science ®Google Scholar
• Regan MM, Francis PA, Pagani O, et al. Absolute benefit of adjuvant endocrine therapies for premenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: TEXT and SOFT Trials. J Clin Oncol. 2016;34:2221–2231.
   PubMed Web of Science ®Google Scholar
• Papakonstantinou A, Foukakis T, Rodriguez-Wallberg KA, et al. Is estradiol monitoring necessary in women receiving ovarian suppression for breast cancer? J Clin Oncol. 2016;34:1573–1579.
   PubMed Web of Science ®Google Scholar
• Dowsett M, Lonning PE, Davidson NE. Incomplete estrogen suppression with gonadotropin-releasing hormone agonists may reduce clinical efficacy in premenopausal women with early breast cancer. J Clin Oncol. 2016;34:1580–1583.
   PubMed Web of Science ®Google Scholar
• Controlled trial of tamoxifen as adjuvant agent in management of early breast cancer. Interim analysis at four years by nolvadex adjuvant trial organisation. Lancet. 1983;1:257–261.
   PubMed Web of Science ®Google Scholar
• Baum M, Brinkley DM, Dossett JA, et al. Improved survival among patients treated with adjuvant tamoxifen after mastectomy for early breast cancer. Lancet. 1983;2:450.
   PubMed Web of Science ®Google Scholar
• Swedish Breast Cancer Cooperative Group. Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. Swedish breast cancer cooperative group. J Natl Cancer Inst. 1996;88:1543–1549.
   PubMed Web of Science ®Google Scholar
• Hershman DL. Sticking to it: improving outcomes by increasing adherence. J Clin Oncol. 2016;34:2440–2442.
   PubMed Web of Science ®Google Scholar
• Partridge AH, Wang PS, Winer EP, et al. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol. 2003;21:602–606.
   PubMed Web of Science ®Google Scholar
• Kimmick G, Anderson R, Camacho F, et al. Adjuvant hormonal therapy use among insured, low-income women with breast cancer. J Clin Oncol. 2009;27:3445–3451.
   PubMed Web of Science ®Google Scholar
• Neugut AI, Hillyer GC, Kushi LH, et al. Non-initiation of adjuvant hormonal therapy in women with hormone receptor-positive breast cancer: the Breast cancer quality of care study (BQUAL). Breast Cancer Res Treat. 2012;134:419–428.
   PubMed Web of Science ®Google Scholar
• Chirgwin JH, Giobbie-Hurder A, Coates AS, et al. Treatment adherence and its impact on disease-free survival in the breast international group 1-98 trial of tamoxifen and letrozole, alone and in sequence. J Clin Oncol. 2016;34:2452–2459.
   PubMed Web of Science ®Google Scholar
• McCowan C, Wang S, Thompson AM, et al. The value of high adherence to tamoxifen in women with breast cancer: a community-based cohort study. Br J Cancer. 2013;109:1172–1180.
   PubMed Web of Science ®Google Scholar
• Nestoriuc Y, von Blanckenburg P, Schuricht F, et al. Is it best to expect the worst? Influence of patients’ side-effect expectations on endocrine treatment outcome in a 2-year prospective clinical cohort study. Ann Oncol. 2016;27:1909–1915.
   PubMed Web of Science ®Google Scholar
• Wolf DM, Jordan VC. The estrogen receptor from a tamoxifen stimulated MCF-7 tumor variant contains a point mutation in the ligand binding domain. Breast Cancer Res Treat. 1994;31:129–138.
   PubMed Web of Science ®Google Scholar
• Levenson AS, Catherino WH, Jordan VC. Estrogenic activity is increased for an antiestrogen by a natural mutation of the estrogen receptor. J Steroid Biochem Mol Biol. 1997;60:261–268.
   PubMed Web of Science ®Google Scholar
• Zhang QX, Borg A, Wolf DM, et al. An estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancer. Cancer Res. 1997;57:1244–1249.
   PubMed Web of Science ®Google Scholar
• Wrenn CK, Katzenellenbogen BS. Structure-function analysis of the hormone binding domain of the human estrogen receptor by region-specific mutagenesis and phenotypic screening in yeast. J Biol Chem. 1993;268:24089–24098.
   PubMed Web of Science ®Google Scholar
• Brzozowski AM, Pike AC, Dauter Z, et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature. 1997;389:753–758.
   PubMed Web of Science ®Google Scholar
• Shiau AK, Barstad D, Loria PM, et al. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell. 1998;95:927–937.
   PubMed Web of Science ®Google Scholar
• Abderrahman B, Jordan VC. Improving long-term adjuvant anti-oestrogenic therapy for breast cancer. Clin Pharmacist. 2016;8:180–190.
   Google Scholar
• Robertson JF, Bondarenko IM, Trishkina E, et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Lancet. 2016;388:2997–3005.
   PubMed Web of Science ®Google Scholar
• Welshons WV, Jordan VC. Adaptation of estrogen-dependent MCF-7 cells to low estrogen (phenol red-free) culture. Eur J Cancer Clin Oncol. 1987;23:1935–1939.
   PubMedGoogle Scholar
• Santen RJ, Brodie H, Simpson ER, et al. History of aromatase: saga of an important biological mediator and therapeutic target. Endocr Rev. 2009;30:343–375.
   PubMed Web of Science ®Google Scholar
• Gottardis MM, Jordan VC. Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res. 1988;48:5183–5187.
   PubMed Web of Science ®Google Scholar
• Gottardis MM, Jiang SY, Jeng MH, et al. Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens. Cancer Res. 1989;49:4090–4093.
   PubMed Web of Science ®Google Scholar
• Howell A, Dodwell DJ, Anderson H, et al. Response after withdrawal of tamoxifen and progestogens in advanced breast cancer. Ann Oncol. 1992;3:611–617.
   PubMed Web of Science ®Google Scholar
• Osborne CK, Arteaga CL. Role of molecular and genetic markers in breast cancer treatment decisions. J Clin Oncol. 2003;21:285s–287s.
   PubMed Web of Science ®Google Scholar
• Howell A, Robertson JF, Abram P, et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol. 2004;22:1605–1613.
   PubMed Web of Science ®Google Scholar
• Fan P, Agboke FA, Cunliffe HE, et al. A molecular model for the mechanism of acquired tamoxifen resistance in breast cancer. Eur J Cancer. 2014;50:2866–2876.
   PubMed Web of Science ®Google Scholar
• Wolf DM, Jordan VC. A laboratory model to explain the survival advantage observed in patients taking adjuvant tamoxifen therapy. Recent Results Cancer Res. 1993;127:23–33.
   PubMedGoogle Scholar
• Yao K, Lee ES, Bentrem DJ, et al. Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice. Clin Cancer Res. 2000;6:2028–2036.
   PubMed Web of Science ®Google Scholar
• Jordan VC. Linking estrogen-induced apoptosis with decreases in mortality following long-term adjuvant tamoxifen therapy. J Natl Cancer Inst. 2014;106:11.
   Google Scholar
• Song RX, Mor G, Naftolin F, et al. Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17beta-estradiol. J Natl Cancer Inst. 2001;93:1714–1723.
   PubMedGoogle Scholar
• Lewis JS, Meeke K, Osipo C, et al. Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation. J Natl Cancer Inst. 2005;97:1746–1759.
   PubMed Web of Science ®Google Scholar
• Ariazi EA, Cunliffe HE, Lewis-Wambi JS, et al. Estrogen induces apoptosis in estrogen deprivation-resistant breast cancer through stress responses as identified by global gene expression across time. Proc Natl Acad Sci U S A. 2011;108:18879–18886.
   PubMed Web of Science ®Google Scholar
• Haddow A, Watkinson JM, Paterson E, et al. Influence of synthetic oestrogens on advanced malignant disease. Br Med J. 1944;2:393–398.
   PubMedGoogle Scholar
• Lonning PE, Taylor PD, Anker G, et al. High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. Breast Cancer Res Treat. 2001;67:111–116.
   PubMed Web of Science ®Google Scholar
• Anderson GL, Chlebowski RT, Aragaki AK, et al. Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women’s Health Initiative randomised placebo-controlled trial. Lancet Oncol. 2012;13:476–486.
   PubMed Web of Science ®Google Scholar
• Ellis MJ, Gao F, Dehdashti F, et al. Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study. Jama. 2009;302:774–780.
   PubMed Web of Science ®Google Scholar
• Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor–positive advanced breast cancer. New England J Med. 2012;366:520–529.
   PubMed Web of Science ®Google Scholar
• Yardley DA, Noguchi S, Pritchard KI, et al. Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther. 2013;30:870–884.
   PubMed Web of Science ®Google Scholar
• Beaver JA, Park BH. The BOLERO-2 trial: the addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancer. Future Oncol. 2012;8:651–657.
   PubMed Web of Science ®Google Scholar
• Piccart M, Hortobagyi GN, Campone M, et al. Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2dagger. Ann Oncol. 2014;25:2357–2362.
   PubMed Web of Science ®Google Scholar
• Finn RS, Crown JP, Lang I, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015;16:25–35.
   PubMed Web of Science ®Google Scholar
• Turner NC, Ro J, Andre F, et al. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med. 2015;373:209–219.
   PubMed Web of Science ®Google Scholar
• Cristofanilli M, Turner NC, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17:425–439.
   PubMed Web of Science ®Google Scholar
• Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer. New England J Med. 2016;375:1925–1936.
   PubMed Web of Science ®Google Scholar
• Wolff AC. CDK4 and CDK6 inhibition in breast cancer - a new standard. N Engl J Med. 2016;375:1993–1994.
   PubMed Web of Science ®Google Scholar
• Carey LA, Perou CM. Palbociclib–taking breast-cancer cells out of gear. N Engl J Med. 2015;373:273–274.
   PubMed Web of Science ®Google Scholar
• Toy W, Shen Y, Won H, et al. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet. 2013;45:1439–1445.
   PubMed Web of Science ®Google Scholar
• Butt AJ. Overcoming resistance: targeting the PI3K/mTOR pathway in endocrine refractory breast cancer. Cancer Biol Ther. 2011;11:947–949.
   PubMed Web of Science ®Google Scholar
• Schmid P, Pinder SE, Wheatley D, et al. Phase II randomized preoperative window-of-opportunity study of the PI3K inhibitor pictilisib plus anastrozole compared with anastrozole alone in patients with estrogen receptor-positive breast cancer. J Clin Oncol. 2016;34:1987–1994.
   PubMed Web of Science ®Google Scholar
• Cummings SR, Ensrud K, Delmas PD, et al. Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med. 2010;362:686–696.
   PubMed Web of Science ®Google Scholar
• Willson TM, Henke BR, Momtahen TM, et al. 3-[4-(1,2-Diphenylbut-1-enyl)phenyl]acrylic acid: a non-steroidal estrogen with functional selectivity for bone over uterus in rats. J Med Chem. 1994;37:1550–1552.
   PubMed Web of Science ®Google Scholar
• Coelingh Bennink HJ, Verhoeven C, Dutman AE, et al. The use of high-dose estrogens for the treatment of breast cancer. Maturitas. 2017;95:11–23.
   PubMed Web of Science ®Google Scholar
• Jordan VC. Prolonged adjuvant tamoxifen: a beginning not the end. Ann Oncol. 1991;2:481–484.
   PubMed Web of Science ®Google Scholar
• Stoll BA. Arena: overprolonged adjuvant tamoxifen therapy in breast cancer. Ann Oncol. 1991;2:396.
   Web of Science ®Google Scholar